Press Release
AI STUDIOS Expands Sales Training With Emotionally Expressive AI Roleplay
PALO ALTO, Calif, September 15th, 2026 — AI STUDIOS, DeepBrain AI’s enterprise AI video and avatar platform, announced enhanced emotional expression capabilities for AI Roleplay, its interactive training solution designed to help employees practice realistic customer conversations. DeepBrain AI plans to expand the solution across sales, customer service, wealth management and other customer-facing teams.
DeepBrain AI expands AI Roleplay across sales and wealth management markets, targeting industries with frequent customer interactions
AI customers express emotions through lifelike facial expressions and tone of voice, creating training experiences similar to real customer consultations
Companies can build customized training programs based on their products, customer profiles and consultation guidelines
AI Roleplay is a training solution in which AI assumes the role of a customer, allowing employees to repeatedly practice conversations in an environment similar to a real customer interaction. Building on its existing conversation-based training capabilities, DeepBrain AI has made the experience more realistic by enabling AI customers to express emotions through facial expressions and tone of voice and respond differently based on their personalities, interests and attitudes toward the conversation.
Organizations can use AI Roleplay to create a variety of situations commonly encountered in customer-facing roles, including customers who show little interest in a product, question the information they receive, compare multiple options or continue asking technical questions. Participants repeatedly practice the full customer conversation, from identifying customer needs and explaining products to responding to questions and objections.
Rather than repeating predetermined answers, AI customers react differently depending on how each conversation develops. Participants must pay attention to the customer’s facial expressions, tone of voice and the overall direction of the discussion as they determine how to respond. This allows employees to build practical communication skills in a more realistic environment than training based solely on prerecorded videos or memorized scripts.
AI Roleplay also provides analysis and coaching throughout the conversation. The solution analyzes each participant’s speaking pace, intonation and facial expressions to provide real-time feedback. After the session, it reviews the full conversation and identifies what the participant handled effectively, what needs improvement and which expressions could be refined. Participants can review their approach and repeat situations in which their response could have been stronger.
Organizations can customize the training experience to reflect their own business environments. Product and service information, key customer profiles, conversation guidelines and successful sales practices can be incorporated into AI customer personas and evaluation criteria. This enables companies to build training around situations employees frequently encounter, apply consistent standards across teams and locations, and update scenarios as products, services or policies change.
AI Roleplay is already being used across a range of customer-facing functions, including insurance sales training, contact center training, in-store customer service and interactive learning following instructor-led courses. Wealth management and financial advisory teams can rehearse how to identify a client’s financial goals, explain financial products clearly and respond to concerns. Other sales teams can practice each stage of the customer conversation, from discovery and product recommendations to price objections and purchase decisions.
The solution can also help reduce the operational burden associated with traditional instructor-led roleplay. New employees can experience a wider range of customer situations before handling live conversations, while experienced employees can focus on difficult customer profiles or complex scenarios. Organizations can evaluate conversations using consistent standards while helping employees strengthen their customer-facing and sales capabilities.
“In sales and financial services, product knowledge is only part of what builds customer trust. Employees must also understand how customers are reacting and respond with language that fits the moment,” said Eric Jang, CEO of DeepBrain AI. “AI Roleplay allows employees to practice with customers who express different emotions and behaviors, review their own approach and improve before the real conversation. By incorporating each organization’s sales expertise and training standards, we aim to help teams strengthen their customer communication skills and support meaningful improvements in sales performance.”
DeepBrain AI plans to expand AI Roleplay across financial services, retail, automotive, telecommunications, education and other industries where customer interactions play a critical role. By connecting live conversations with AI customers, real-time coaching, post-session analysis and repeated practice, the company aims to help enterprises develop customer-facing talent and improve frontline readiness.
About DeepBrain AI
DeepBrain AI develops AI video generation, AI Human and conversational AI solutions for enterprises. Its flagship platform, AI STUDIOS, enables organizations to create AI-powered video content and interactive avatar experiences for corporate training, financial services, retail, media and customer service.
Through AI STUDIOS, organizations can create and deliver video content, build interactive AI experiences and provide scalable training across teams and locations. DeepBrain AI also develops customized AI Human and AI agent solutions for enterprise, public-sector and educational organizations. The company operates a U.S. office in Palo Alto, California. For more information, visit AI STUDIOS.n
Media Contact:
DeepBrain AI Communications
www.aistudios.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
PrimeXBT Launches AI-Assisted Trading with MCP Integration, Connecting ChatGPT and Claude to Trading Accounts
Castries, Saint Lucia, November 4th, 2026, FinanceWire
PrimeXBT, a global multi-asset broker and crypto asset service provider, has announced the launch of its Model Context Protocol (MCP) integration, enabling traders to connect AI assistants, such as ChatGPT and Claude, directly to their trading accounts. The launch, alongside a new Trading API, expands PrimeXBT’s AI and automation capabilities, introducing new ways for clients to access market information, manage their accounts, and interact with financial markets.
With PrimeXBT MCP, traders can connect their preferred AI assistant using just one link and a PrimeXBT login, without coding or API key configuration. Designed for both new and experienced traders, the integration provides tools, allowing clients to monitor their accounts, explore market prices and charts, review trading history and understand trading conditions through natural-language conversations. Powered by live account data and PrimeXBT’s built-in knowledge base, it delivers relevant, account-specific answers to questions about trading costs, leverage, margin requirements, and platform rules, reducing the need to navigate multiple screens or search for information manually.
MCP also supports AI-assisted trade execution, enabling clients to prepare market, limit, and stop orders and preview estimated prices, fees, margin requirements, leverage, and liquidation levels, calculated by PrimeXBT’s trading engine. Every order requires explicit trader confirmation before execution, with Read-only and Read & Trade permissions available. For added security, the MCP does not allow withdrawals or fund transfers through AI assistants. The integration is available for demo and live accounts on the broker’s PXTrader 2.0 platform, covering CFDs and Crypto Futures.
Commenting on the launch, Jonatan Randin, Senior Market Analyst, said: “AI has become part of everyday life, changing how people access information, use technology and make decisions. We believe trading should evolve in the same direction. With our MCP, we’re bringing real trading data and functionality into the AI assistants people already know and use, making trading more accessible, simplifying complex processes and giving traders greater flexibility in how they interact with markets, while keeping them in control. This is an important step towards a more connected and intuitive trading experience.”
PrimeXBT MCP is built on the broker’s Trading API, which has also been introduced to expand PXTrader 2.0’s capabilities for algorithmic, quantitative and technically experienced traders. The API enables clients to connect their own trading bots, applications and external tools, automate strategies around the clock and access account and market data programmatically. It supports order and position management, custom dashboards and analytics, with security features including two-factor authentication, configurable permissions and optional IP restrictions. Deposits, withdrawals and fund transfers are not supported through the API.
The launch builds on PrimeXBT’s continued development of PXTrader 2.0, its native platform for trading CFDs and Crypto Futures, bringing together advanced trading tools, flexible fiat and crypto funding options, crypto-denominated accounts and competitive trading conditions. As AI continues to transform financial technology, PrimeXBT remains committed to integrating emerging technologies into its trading infrastructure, strengthening its position as a forward-thinking broker and driving the next generation of trading innovation.
To learn more about MCP integration, users can visit PrimeXBT website.
About PrimeXBT
PrimeXBT is a global multi-asset broker and crypto asset service provider trusted by traders in more than 150 countries. The platform bridges traditional and digital markets within one integrated environment, redefining versatility and innovation in online trading. Clients can access Forex, CFDs on indices, commodities, shares, crypto, and Crypto Futures, as well as buy, store, and exchange cryptocurrencies. This unified experience extends across both the native PXTrader 2.0 platform and MetaTrader 5, supported by advanced risk-management tools and a wide range of funding options in crypto, fiat, and local payment methods. Since 2018, PrimeXBT has focused on empowering traders through broad multi-asset access, fair and transparent conditions, professional-grade technology and dedicated human support. By combining expertise, trust, and a client-first approach, PrimeXBT sets a benchmark of excellence in the financial industry and provides traders with the tools they need to trade, grow, and succeed with confidence.
Disclaimer: The content provided here is for informational purposes only and is not intended as personal investment advice and does not constitute a solicitation or invitation to engage in any financial transactions, investments, or related activities. Past performance is not a reliable indicator of future results. The financial products offered by the Company are complex and come with a high risk of losing money rapidly due to leverage. These products may not be suitable for all investors. Before engaging, you should consider whether you understand how these leveraged products work and whether you can afford the high risk of losing your money. The Company does not accept clients from the Restricted Jurisdictions as indicated on its website / T&Cs. Some products and services, including MT5, may not be available in your jurisdiction. The applicable legal entity and its respective products and services depend on the client’s country of residence and the entity with which the client has established a contractual relationship during registration.
Contact
PrimeXBT
pr@primexbt.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Joseph Grinkorn: Elon Musk and Starlink Could Take Over the Global Telecom Industry Within Three Years – Traditional Telecom Giants on Notice
Morris Group CEO Predicts a Massive Telecommunications Revolution as Satellite Technology Threatens to Make Traditional Cellular Networks Obsolete
NEW YORK, NY, USA – Joseph Grinkorn, investment expert and CEO of Morris Group, is making another bold prediction: Elon Musk’s Starlink could become one of the most powerful forces in global telecommunications, fundamentally changing how the world communicates within the next three years.
Grinkorn believes Musk is preparing to disrupt an industry that has been dominated for decades by traditional mobile carriers and Internet providers. With SpaceX’s rapidly expanding satellite network and Starlink’s direct-to-cell ambitions, the future of telecommunications may no longer depend on thousands of cellular towers and traditional infrastructure.
The numbers show how fast that network is growing. Starlink passed 12 million subscribers by mid-2026 and now operates more than 10,000 satellites in low Earth orbit. In 2025, SpaceX also agreed to acquire EchoStar’s AWS-4 and H-block spectrum licenses in a deal worth about $17 billion. U.S. regulators cleared the sale in May 2026, giving Starlink frequencies of its own for direct-to-cell service.
Grinkorn identifies several reasons why Starlink could become the next global telecommunications powerhouse:
- The End of Traditional Telecom Dominance: Starlink could challenge the business models of major cellular providers by delivering connectivity directly from space.
- A Global Mobile Network: Satellite-to-cell technology could eventually allow consumers to connect their smartphones virtually anywhere on Earth. SpaceX has already launched more than 600 direct-to-cell satellites.
- Internet Without Borders: Starlink has the potential to eliminate geographical limitations and bring high-speed connectivity to underserved markets worldwide. The service already reaches customers in more than 160 countries and territories.
- A Trillion-Dollar Industry at Risk: Traditional telecommunications companies could face enormous competitive pressure as satellite technology advances.
- Musk’s Next Billion-Dollar Revolution: Following the overhaul of electric vehicles and commercial spaceflight, Musk could now reshape the global communications industry.
- The Three-Year Window: Grinkorn believes the next three years could be critical in determining the future leaders of the global telecommunications market.
Joseph Grinkorn’s Statement
“Elon Musk isn’t simply building another Internet company. He’s building the infrastructure for the future of global communications. I believe we are approaching a point where satellites could fundamentally change the way the world connects.
Traditional telecom companies should be very concerned. Starlink has the potential to become a dominant global communications platform, and investors who underestimate this change could miss one of the biggest technological shifts of our generation.”
Grinkorn believes the telecommunications industry is approaching a historic turning point and that Starlink could emerge as one of the most important companies in the global technology and communications market.
What Comes Next
Carriers are already adjusting. EchoStar’s Boost Mobile customers are set to gain access to Starlink’s direct-to-cell service, and T-Mobile has worked with Starlink on satellite texting in the United States. SpaceX has also set a target of user speeds up to 150 Mbps for its upgraded direct-to-cell service.
Watch how fast carriers sign satellite partnerships and how quickly subscriber numbers climb. Those signals will show whether the three-year window Grinkorn describes is opening on schedule.
About Joseph Grinkorn & The Morris Group
Joseph Grinkorn is a Wall Street investment expert and entrepreneur with over 20 years of experience across banking, finance, and real estate. As the founder and CEO of Morris Group, he has built a reputation for accurate market predictions and forward-looking investment strategies. He is frequently featured in the financial press for his insights on equity markets, tariffs, and global trade. Over the past decade, Grinkorn has been actively involved in investments across a broad range of industries and sectors, successfully identifying opportunities and executing some of the most notable private-market transactions across the business and investment landscape.
Founded in 2007, Morris Group is an international investment firm headquartered in New York City. The company operates three divisions: Morris Group Financial, focused on equity investments in technology and social media companies; Morris Group Properties, specializing in high-return real estate investments; and Morris Group Funding, providing commercial financing solutions. With its data-driven approach, transparency, and commitment to growing client returns, Morris Group has established itself as a trusted leader in the investment sector.
Media Contact
Company Name: Morris Group
Phone: (646) 673-8404
Country: United States
Website: www.morris-group.co
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
CMS(867.HK/8A8.SG): Ruxolitinib Phosphate Cream Approved in Singapore, Filling Gap in Vitiligo Treatment
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Rxilient Medical received approval from the Health Sciences Authority of Singapore (HSA) on 3 November 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product” or “Lumirix®”) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. It is the first and only topical prescription drug in Singapore that directly targets the pathophysiological mechanism of vitiligo[1], meeting a long-standing unmet clinical need.
This approval fills a gap in the field of vitiligo treatment in Singapore. In addition to Singapore, Rxilient Medical has already launched sales of Lumirix® (vitiligo indication) in Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan Region.
Since 2022, the Group has launched its “Industry Internationalization” strategy, using Singapore as its business hub in emerging markets to build a highly efficient and collaborative value loop across the entire industry chain of “R&D, production, and sales.” Rxilient Medical is the Group’s commercialization subsidiary for entering emerging markets. With “global localization” as its core strategy, it is committed to bringing innovative global therapies to emerging markets and benefiting local patients through its full-chain commercialization capabilities covering drug import, development, registration, and marketing. Rxilient Medical is operated by a professional and highly experienced localized team. Headquartered in Singapore, the company has established subsidiaries or offices in Hong Kong Special Administrative Region, Taiwan Region, Malaysia, Vietnam, the Philippines, Indonesia, Thailand, and the UAE. By the end of June 2026, Rxilient Medical had achieved sales for a cumulative total of 9 products across multiple countries and regions in Southeast Asia, and had cumulatively submitted marketing applications for more than 20 pharmaceutical products and medical devices, mapping out a robust and continuous product launch blueprint.
About Vitiligo
Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that approximately 0.7% of Singapore’s population suffers from vitiligo[2]. For decades, dermatologists in Singapore have relied on treatments such as steroids, calcineurin inhibitors, and phototherapy — therapies that fail to specifically or adequately target the pathogenesis of vitiligo. The approval of Lumirix® in Singapore represents the first drug specifically for the regeneration of pigment in non-segmental vitiligo, filling a gap in the field of vitiligo treatment.
More About Ruxolitinib Phosphate Cream
Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is the first and only drug approved for the repigmentation of non-segmental vitiligo by the U.S. Food and Drug Administration (FDA)[3]. In the U.S., ruxolitinib phosphate cream is indicated for the topical treatment of non-segmental vitiligo in adult and pediatric patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients aged 2 years and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not advisable. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo in adults and adolescents aged 12 years and older with facial involvement, and moderate atopic dermatitis in adults whose disease remains inadequately controlled despite treatment with topical corticosteroids and topical calcineurin inhibitors[4].
In January 2026, ruxolitinib phosphate cream was approved for marketing by the National Medical Products Administration (NMPA) of China, becoming the first topical JAK inhibitor approved in China for the treatment of vitiligo, and has since been commercialized in China. Subsequently, in September 2026, the Product was approved for an additional indication of mild to moderate atopic dermatitis (“AD”), for the topical short-term and non-continuous chronic treatment of mild to moderate AD in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with other topical therapies or when those therapies are not advisable. This further expands the Product’s application in the field of dermatological diseases.
In two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[5].
The Group, through a subsidiary of Dermavon, entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary).
Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. Lumirix® is a registered trademark of the Group.
About CMS
CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, CMS enables each medicine to fully realize both its clinical value and commercial value.
Focusing on unmet clinical needs, CMS efficiently advances the research, clinical development and regulatory approval of differentiated specialty medicines. Drawing on evidence-based medicine and long-standing expertise across specialty therapeutic areas, CMS establishes the medical positioning of its products. Through a professional academic promotion system, CMS drives clinical recognition and large-scale application of its products, translating clinical value into enduring brand competitiveness.
CMS focuses on specialty areas including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. It continuously expands its product portfolio, fostering a tiered structure of marketed products and innovative pipeline candidates, and leverages its solid medical expertise and omni-channel commercialization network to drive the growth of new products. Within the Group, its skin health business, Dermavon, has grown into a leading innovative pharmaceutical company in China’s skin health sector. Meanwhile, CMS is expanding its international business with Southeast Asia as a base, advancing product introduction, registration and commercialization in line with local healthcare needs, while progressively optimizing its regional manufacturing footprint to strengthen localized operations and supply capabilities.
Reference:
2.Chan MF, Thng S. et al. Investigating factors associated with quality of life of vitiligo patients in Singapore, International Journal of Nursing Practice 2013; 19 (Suppl. 3), 3–10
3.The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream
4.The EMA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar
5.The clinical studies information can be found on the Opzelura® official website, as follows: https://www.opzelura.com/opzelura-prescribing-information
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
PrimeXBT Launches AI-Assisted Trading with MCP Integration, Connecting ChatGPT and Claude to Trading Accounts
CMS(867.HK/8A8.SG): Ruxolitinib Phosphate Cream Approved in Singapore, Filling Gap in Vitiligo Treatment
Joseph Grinkorn: Elon Musk and Starlink Could Take Over the Global Telecom Industry Within Three Years – Traditional Telecom Giants on Notice
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release4 days ago
A Better Life Through Ai Wheel Mobility Scooter 20 inch Boarding Luggage: Airwheel Smart Carry on hand Luxury Cabin Suitcase Shine at the 140th Canton Fair
-
Press Release4 days ago
Soika Labs Launches Mockingjay Network, an Agentic AI Operating System That Lets Businesses Command Their Own AI Workforce
-
Press Release5 days ago
AIXONA Announces AI-Powered Transaction Optimization and Expansion into European and Canadian Markets
-
Press Release7 days ago
FinSight Ventures Launches $100 Million Physical AI Index Fund
-
Press Release6 days ago
Alex Cecola Highlights Why Investment Process Matters More Than Market Prediction for Long- Term Investors
-
Press Release4 days ago
Remittances to Uzbekistan Reach $18.9bn as OSON X Opens a UAE Money App for Central Asians
-
Press Release4 days ago
Aussie Vape Trend Scales Wholesale Supply Network Across Australia
-
Press Release4 days ago
Rossi Paola Vargas Daly Connects Public Health Research and Criminal Law